-
Mashup Score: 92Completion Of Pembrolizumab In advanced non-small cell Lung cancer – real world Outcomes after Two years of therapy (COPILOT) - 21 day(s) ago
Immune checkpoint inhibitor (ICI)’s targeting the programmed-death-1/programmed-death ligand 1 (PD-1/PD-L1) axis have established themselves as part of the first line management of metastatic non-small cell lung cancer (NSCLC) without actionable driver mutations. Pembrolizumab, an ICI directed against PD-1, has been shown in four practice changing first line phase III randomised controlled trials to improve overall survival alone, or in combination with chemotherapy, compared to chemotherapy alone in patients with advanced NSCLC1-4.
Source: www.clinical-lung-cancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 40Clinical utility of circulating tumor DNA in patients with advanced KRASG12C-mutated non-small cell lung cancer treated with sotorasib. - 22 day(s) ago
For patients with KRASG12C-mutated NSCLC who are treated with sotorasib, there is a lack of biomarkers to guide treatment decisions. We therefore investigated the clinical utility of pre-treatment and on-treatment circulating tumor DNA (ctDNA), as well as treatment-emergent alterations upon disease progression.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 23
One of the most frequent oncogenic event in non-small cell lung cancer (NSCLC) is a glycine to cysteine substitution in position 12 in the V-ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene i.e., the KRASG12C mutation, detected in 13 % of the cases [1].
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 104
Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Bristol Myers Squibb (NYSE: BMY) today announced that the pivotal Phase 3 KRYSTAL-12 study, evaluating KRAZATI® (adagrasib) as a monotherapy in patients with pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation, met the primary endpoint of progression-free survival (PFS) and the key secondary endpoint of overall response rate (ORR) as assessed by Blinded Independent Central Review (BICR) at final analysis for these endpoints. The study remains ongoing to assess the additional key secondary endpoint of overall survival. Results of the confirmatory trial showed that KRAZATI demonstrated a statistically significant and clinically meaningful benefit in PFS and ORR compared to
Source: news.bms.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 104
Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Bristol Myers Squibb (NYSE: BMY) today announced that the pivotal Phase 3 KRYSTAL-12 study, evaluating KRAZATI® (adagrasib) as a monotherapy in patients with pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation, met the primary endpoint of progression-free survival (PFS) and the key secondary endpoint of overall response rate (ORR) as assessed by Blinded Independent Central Review (BICR) at final analysis for these endpoints. The study remains ongoing to assess the additional key secondary endpoint of overall survival. Results of the confirmatory trial showed that KRAZATI demonstrated a statistically significant and clinically meaningful benefit in PFS and ORR compared to
Source: news.bms.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 104
Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Bristol Myers Squibb (NYSE: BMY) today announced that the pivotal Phase 3 KRYSTAL-12 study, evaluating KRAZATI® (adagrasib) as a monotherapy in patients with pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation, met the primary endpoint of progression-free survival (PFS) and the key secondary endpoint of overall response rate (ORR) as assessed by Blinded Independent Central Review (BICR) at final analysis for these endpoints. The study remains ongoing to assess the additional key secondary endpoint of overall survival. Results of the confirmatory trial showed that KRAZATI demonstrated a statistically significant and clinically meaningful benefit in PFS and ORR compared to
Source: news.bms.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 50Clinical and Genomic Characterization of Long-Term Responders Receiving Immune Checkpoint Blockade for Metastatic Non–Small-Cell Lung Cancer - 2 month(s) ago
MicroabstractOur retrospective study aims to explore the clinical and genomic underpinnings of a durable response to ICI. We identify lower ECOG performance status at diagnosis, the absence of liver metastases at diagnosis and occurrence of irAEs as predictors of a prolonged response. These findings help inform on therapeutic selection and personalized discussions of benefit to patients with lung cancer.
Source: www.clinical-lung-cancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 150
KRAS mutations(m) are the most common oncogenic alterations in NSCLC, occurring in 20–40 % of lung adenocarcinomas [1–3]. While KRAS has been historically considered undruggable, two KRAS G12C inhibitors are now FDA approved [4,5] and there is a suite of emerging KRAS-directed agents in development [6]. Understanding the relative therapeutic benefit of these novel agents, as well as designing clinical trials with prognostic balance between arms, will require a thorough understanding of outcomes and treatment responsiveness of KRASm aNSCLC across subgroups defined by KRASm subtype, PD-L1 status, and comutations.
Source: www.lungcancerjournal.infoCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38Sotorasib in KRAS G12C-Mutated Non-Small Cell Lung Cancer: A Multicenter Real-World Experience from the Compassionate Use Program in Germany - 3 month(s) ago
Sotorasib is a first-in-class KRAS p.G12C-inhibitor that has entered clinical trials in pretreated patients with non-small cell lung cancer (NSCLC) in 2018. First response rates were promising in the CodeBreaK trials. It remains unclear whether response to sotorasib and outcomes differ in a real-world setting when including patients underrepresented in clinical trials.
Source: www.ejcancer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 63
CNS metastases occur in 27%-42% of patients with non–small-cell lung cancer (NSCLC) that harbor KRAS G12C mutations at diagnosis. 1 – 4 Prognosis is worse and the incidence of CNS failure is higher in patients with KRAS -mutated NSCLC and CNS metastases, compared with patients without KRAS mutations. 5 – 8 Adagrasib, a KRAS G12C inhibitor, was granted accelerated approval by the US Food and Drug Administration in December 2022 for the treatment of adult patients with KRAS G12C -mutated locally advanced
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
Real world description of pts who completed 2y of 1L pembrolizumab @ClinicalLung (n=71). In this group, RR 79%, mPFS 46.1m, 60% with #KRAS mt. 24% received local ablation for oligoprogression. 28% progressed after stopping pembro (more if PDL1 < 1%). https://t.co/RNsHzaBx6n